These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30146956)

  • 21. Increasing access to medicines.
    Finch R; Garner S
    BMJ; 2009 Apr; 338():b1397. PubMed ID: 19351679
    [No Abstract]   [Full Text] [Related]  

  • 22. Securing access to effective antibiotics for current and future generations. Whose responsibility?
    Cars O
    Ups J Med Sci; 2014 May; 119(2):209-14. PubMed ID: 24766475
    [No Abstract]   [Full Text] [Related]  

  • 23. Improving antibiotic markets for long-term sustainability.
    Kesselheim AS; Outterson K
    Yale J Health Policy Law Ethics; 2011; 11(1):101-67. PubMed ID: 21381513
    [No Abstract]   [Full Text] [Related]  

  • 24. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics.
    Renwick MJ; Brogan DM; Mossialos E
    J Antibiot (Tokyo); 2016 Feb; 69(2):73-88. PubMed ID: 26464014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All.
    Bhatti T; Lum K; Holland S; Sassman S; Findlay D; Outterson K
    J Law Med Ethics; 2018 Jun; 46(1_suppl):59-65. PubMed ID: 30146959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
    Pekarsky B
    Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption.
    Al-Haroni M; Skaug N
    J Antimicrob Chemother; 2007 Jun; 59(6):1161-6. PubMed ID: 17446241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibiotic Resistance: The Need For a Global Strategy.
    Elder DP; Kuentz M; Holm R
    J Pharm Sci; 2016 Aug; 105(8):2278-87. PubMed ID: 27397433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug development: Time for teamwork.
    May M
    Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract]   [Full Text] [Related]  

  • 31. [New antibiotics for the clinical setting, an overview].
    Meylan S; Portillo Tunon V; Guery B
    Rev Med Suisse; 2020 Apr; 16(690):713-718. PubMed ID: 32301304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The consequences of generic marketing on antibiotic consumption and the spread of microbial resistance: the need for new antibiotics.
    Toutain PL; Bousquet-Melou A
    J Vet Pharmacol Ther; 2013 Oct; 36(5):420-4. PubMed ID: 23713785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotic innovation for future public health needs.
    Theuretzbacher U
    Clin Microbiol Infect; 2017 Oct; 23(10):713-717. PubMed ID: 28652114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An antibiotic's journey from marketing authorization to use, Norway.
    Årdal C; Blix HS; Plahte J; Røttingen JA
    Bull World Health Organ; 2017 Mar; 95(3):220-226. PubMed ID: 28250535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development: A Multi-Actor and System-Level Analysis.
    Baraldi E; Ciabuschi F; Leach R; Morel CM; Waluszewski A
    Am J Law Med; 2016 May; 42(2-3):451-486. PubMed ID: 29086643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012.
    Both L; Botgros R; Cavaleri M
    Euro Surveill; 2015; 20(34):30002. PubMed ID: 26530125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introduction and geographic availability of new antibiotics approved between 1999 and 2014.
    Kållberg C; Årdal C; Salvesen Blix H; Klein E; M Martinez E; Lindbæk M; Outterson K; Røttingen JA; Laxminarayan R
    PLoS One; 2018; 13(10):e0205166. PubMed ID: 30325963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Programs and Discoveries Aim to Combat Antibiotic Resistance.
    Hampton T
    JAMA; 2015 Jun 23-30; 313(24):2411-3. PubMed ID: 26039283
    [No Abstract]   [Full Text] [Related]  

  • 39. Implementing transnational telemedicine solutions: a connected health project in rural and remote areas of six Northern Periphery countries Series on European collaborative projects.
    Casey M; Hayes PS; Heaney D; Dowie L; Ólaighin G; Matero M; Hun S; Knarvik U; Alrutz K; Eadie L; Glynn LG
    Eur J Gen Pract; 2013 Mar; 19(1):52-8. PubMed ID: 23432039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pay drug companies $1bn for each new antibiotic, says report.
    Owen J
    BMJ; 2016 May; 353():i2863. PubMed ID: 27198868
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.